A case of carcinosarcoma of uterine endometrium associated with Tamoxifen use in breast cancer patient.
- Author:
Jun Mo AHN
1
;
Shin Ah KIM
;
Seok Min LEE
;
Yun Hee LEE
;
Dae Won KIM
;
Jib Kwang CHUNG
;
Seong Uk KIM
;
Hwan Sung JOE
;
Im Soon LEE
;
Dong Won KIM
Author Information
1. Department of Obstetrics & Gynecology, College of Medicine, Soonchunhyung University, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
Tamoxifen;
Carcinosarcoma
- MeSH:
Breast Neoplasms*;
Breast*;
Carcinosarcoma*;
Endometrial Hyperplasia;
Endometrial Neoplasms;
Endometrium*;
Female;
Humans;
Mastectomy, Modified Radical;
Ovary;
Polyps;
Tamoxifen*;
Uterus
- From:Korean Journal of Obstetrics and Gynecology
2002;45(7):1236-1240
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Tamoxifen, which is often used in breast cancer therapy, has also been used in the treatment of patients with advanced and recurrent endometrial carcinoma. Tamoxifen has been shown to have significant benificial effects in the treatment of breast cancer patients as hormonal therapy. However, there is evidence that tamoxifen may affect other hormone sensitive organs, including the uterus and ovaries. An increased risk of endometrial polyps, endometrial hyperplasia and endometrial cancer has been reported in tamoxifen treated women. We are able to make this report because we have experienced uterine endometrial carcinosarcoma which is developed in a patient treated with tamoxifen for five years following a modified radical mastectomy due to breast cancer in our hospital.
